PubRank

John Forsayeth

Author PubWeight™ 55.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 2012 2.42
2 Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006 2.41
3 Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc 2005 1.74
4 Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012 1.70
5 Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A 2009 1.70
6 An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J Neurosci 2010 1.59
7 Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther 2009 1.55
8 Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 2012 1.55
9 Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage 2008 1.53
10 Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 2013 1.52
11 Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009 1.46
12 Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 2009 1.36
13 Current status of gene therapy trials for Parkinson's disease. Exp Neurol 2007 1.34
14 Striatal volume differences between non-human and human primates. J Neurosci Methods 2008 1.33
15 Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 2010 1.32
16 Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol 2005 1.32
17 Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 2010 1.31
18 Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods 2009 1.25
19 Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 2009 1.24
20 Real-time imaging and quantification of brain delivery of liposomes. Pharm Res 2006 1.22
21 Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 2009 1.21
22 Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol 2007 1.21
23 Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 2010 1.14
24 Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective. Exp Neurol 2007 1.14
25 Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther 2010 1.09
26 Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery 2010 1.05
27 Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage 2010 1.02
28 Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther 2012 1.02
29 Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys. Neuroreport 2006 1.00
30 Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg 2010 0.99
31 Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther 2008 0.98
32 Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol 2010 0.97
33 Convection-enhanced delivery of liposomes to primate brain. Methods Enzymol 2009 0.96
34 Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res 2009 0.93
35 Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis 2011 0.93
36 Evaluation of doxorubicin-loaded 3-helix micelles as nanocarriers. Biomacromolecules 2013 0.92
37 Transduction of antigen-presenting cells in the brain by AAV9 warrants caution in preclinical studies. Mol Ther 2015 0.90
38 Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther 2012 0.89
39 Guided delivery of adeno-associated viral vectors into the primate brain. Adv Drug Deliv Rev 2011 0.86
40 Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A. Mol Ther 2012 0.84
41 Anatomic compression caused by high-volume convection-enhanced delivery to the brain. Neurosurgery 2009 0.82
42 Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain. Neuropharmacology 2010 0.81
43 Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system. PLoS One 2011 0.80
44 Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics 2013 0.77
45 Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine (Lond) 2014 0.76
46 Systemic rapamycin alone may not be a treatment option for malignant glioma: evidence from an in vivo study. J Neurooncol 2012 0.75